ASH: AlloHSCT Feasible After PD-1, PD-L1 mAb in Hodgkin Lymphoma
Outcomes good for those treated with a PD-1 or PD-L1 inhibitor before undergoing allogeneic HSCT.
Diagnosis & Disease Information
Evidence Supports Outpatient Management of Some Children With AML Undergoing Intensive Chemotherapy
Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
High Use of Oncology Nurse Navigators Showed Similar Clinical Outcomes for White, Nonwhite Patients with DLBCL
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
Cell Therapy Transplant Approach Holds Early Promise for Patients With Sickle Cell Disease
Researchers assessed a method of extracting marrow cells and transforming them to promote fetal hemoglobin generation in patients with sickle cell disease.
Postremission Oral Azacitidine Maintenance Therapy Proposed As a New Standard of Care in Some Patients With AML
Eligibility criteria for this study included intermediate- or high-risk cytogenetics, and CR or CR with incomplete count recovery following induction chemotherapy.
Addition of Aspirin to Direct-Acting Oral Anticoagulation May Increase Bleeding Risk
Adding aspirin to direct-acting oral anticoagulant therapy without a clear indication may increase bleeding risk without decreasing thrombotic risk.
Emicizumab Yields Clinically Relevant Improvement in Joint Health in Hemophilia A
Patients with hemophilia A reported a median improvement of 2.25 points in hemophilia joint health score during the course of the study.
Factor XI Deficiency Linked To Increased Risk for Postpartum Hemorrhage With Cesarean Delivery
Risk for postpartum hemorrhage after cesarean delivery was nearly 2-fold greater in patients with mild factor XI deficiency compared with the control cohort.
Better Short-Term QoL, Fewer Symptoms With CAR-T vs SCT in Hematologic Malignancies
While PRO-CTCAEs capture patient reports of particular symptomatic AEs, the “toxicity over time” approach provides a longitudinal assessment of these AEs.
CAR-T Therapy May Be Associated With Decreased Utilization of Health Care Resources in Older, “Real-World” Patients With NHL
In this study, claims data from CMS were used to estimate health care utilization of patients with DLCBL before and after CAR-T therapy.
- Loading...
Loading...
Next post in ASH 2019
Loading... 
Loading...